The global ultrasound guided breast biopsy market size was estimated to be USD 725 million in 2023 and is expected to reach at USD 1725.2 million by 2033 with a CAGR of 8.2% during the forecast period 2023-2033. Increasing prevalence of breast cancer, advancements in imaging technology, non-invasive and minimally invasive procedures, rising awareness and screening programs, and technological advancements in biopsy devices will drive the market growth.
The development of 3D and 4D ultrasound systems is just one example of the enormous developments in ultrasound imaging technology. The market is expanding as a result of these technical developments' better accuracy and precision of ultrasound-guided breast biopsies. For instance, Hologic's LOCalizerTM wireless breast lesion localization system obtained FDA approval in March 2023, offering a wire-free alternative to wire localization in breast cancer surgery. For instance, Siemens Healthineers stated in May 2023 that their ACUSON Sequoia ultrasound system, which has cutting-edge imaging capabilities for breast imaging and biopsy operations, would be available.
By product type, biopsy systems was the highest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the increasing adoption of advanced biopsy systems and the rising number of breast cancer cases requiring tissue sampling for accurate diagnosis and treatment planning. For instance, GE Healthcare unveiled their LOGIQTM E10 ultrasound system with AI capabilities in February 2023. This system offers improved imaging and workflow economies for breast imaging and biopsy operations. Biopsy needles will be the fastest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the increasing demand for disposable biopsy needles due to their cost-effectiveness, convenience, and reduced risk of cross-contamination.
By technology, 3D Ultrasound was the highest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to its ability to provide detailed, real-time imaging of breast tissue, leading to improved accuracy and diagnostic outcomes. For instance, Philips Healthcare introduced their EPIQ Elite ultrasound system in January 2023, which includes cutting-edge imaging technology for better biopsy guidance and breast lesion visualisation. 4D Ultrasound will be the fastest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to its ability to provide real-time imaging with the added dimension of time, resulting in enhanced visualization and improved diagnostic accuracy during breast biopsies.
By end-user, Hospitals was the highest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the high patient volume and comprehensive medical services offered by hospitals, making them the primary setting for performing ultrasound-guided breast biopsies. For instance, Fujifilm announced the debut of its new iCADTM Breast AI solution in February 2023. This solution connects with its AMULET Innovality mammography system for enhanced breast lesion identification and diagnosis. Ambulatory Surgical Centers will be the fastest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the increasing adoption of outpatient and minimally invasive procedures, as well as the growing trend towards performing ultrasound-guided breast biopsies in ambulatory surgical centers.
The development of 3D and 4D ultrasound systems is just one example of the enormous developments in ultrasound imaging technology. The market is expanding as a result of these technical developments' better accuracy and precision of ultrasound-guided breast biopsies. For instance, Hologic's LOCalizerTM wireless breast lesion localization system obtained FDA approval in March 2023, offering a wire-free alternative to wire localization in breast cancer surgery. For instance, Siemens Healthineers stated in May 2023 that their ACUSON Sequoia ultrasound system, which has cutting-edge imaging capabilities for breast imaging and biopsy operations, would be available.
By product type, biopsy systems was the highest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the increasing adoption of advanced biopsy systems and the rising number of breast cancer cases requiring tissue sampling for accurate diagnosis and treatment planning. For instance, GE Healthcare unveiled their LOGIQTM E10 ultrasound system with AI capabilities in February 2023. This system offers improved imaging and workflow economies for breast imaging and biopsy operations. Biopsy needles will be the fastest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the increasing demand for disposable biopsy needles due to their cost-effectiveness, convenience, and reduced risk of cross-contamination.
By technology, 3D Ultrasound was the highest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to its ability to provide detailed, real-time imaging of breast tissue, leading to improved accuracy and diagnostic outcomes. For instance, Philips Healthcare introduced their EPIQ Elite ultrasound system in January 2023, which includes cutting-edge imaging technology for better biopsy guidance and breast lesion visualisation. 4D Ultrasound will be the fastest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to its ability to provide real-time imaging with the added dimension of time, resulting in enhanced visualization and improved diagnostic accuracy during breast biopsies.
By end-user, Hospitals was the highest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the high patient volume and comprehensive medical services offered by hospitals, making them the primary setting for performing ultrasound-guided breast biopsies. For instance, Fujifilm announced the debut of its new iCADTM Breast AI solution in February 2023. This solution connects with its AMULET Innovality mammography system for enhanced breast lesion identification and diagnosis. Ambulatory Surgical Centers will be the fastest revenue-grossing segment in the global ultrasound guided breast biopsy market in 2022 owing to the increasing adoption of outpatient and minimally invasive procedures, as well as the growing trend towards performing ultrasound-guided breast biopsies in ambulatory surgical centers.
Global Ultrasound Guided Breast Biopsy, By Region (USD Million)
North America was the highest revenue-grossing segment in the global Ultrasound Guided Breast Biopsy market in 2022 owing to the well-established healthcare infrastructure, high prevalence of breast cancer, and increasing adoption of advanced diagnostic technologies in the region. For instance, Canon Medical Systems' Aplio i900 ultrasound system with improved imaging capabilities for breast imaging and biopsy operations got FDA authorization in September 2022. Asia Pacific will be the fastest revenue-grossing segment in the global Ultrasound Guided Breast Biopsy market in 2022 owing to the increasing awareness about breast cancer, rising healthcare infrastructure, and growing adoption of advanced diagnostic technologies in the region.Global 4D Ultrasound Market (USD Million), 2023 & 2033
This comprehensive research report focuses on the global and regional market size and forecasts from 2022 to 2033.Report Scope:
- Base Year: 2022
- Forecast Period: 2023-2033
- Study Coverage
- Market Forecast by Product type, Technology, End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Ultrasound Guided Breast Biopsy Market Report 2022-2033
Ultrasound Guided Breast Biopsy Market Analysis & Forecast by Product Type 2022-2033 (Revenue USD Mn)
- Biopsy Systems
- Biopsy Needles
- Guidance Systems
Ultrasound Guided Breast Biopsy Market Analysis & Forecast by Application 2022-2033 (Revenue USD Mn)
- 2D Ultrasound
- 3D Ultrasound
- 4D Ultrasound
- Automated Breast Ultrasound
Ultrasound Guided Breast Biopsy Market Analysis & Forecast by End-user 2022-2033 (Revenue USD Mn)
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
Ultrasound Guided Breast Biopsy Market Analysis & Forecast by Region 2022-2033 (Revenue USD Mn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin American
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Ultrasound guided breast biopsy Market: Product Type Estimates & Trend Analysis
8. Ultrasound guided breast biopsy Market: Technology Estimates & Trend Analysis
9. Ultrasound guided breast biopsy Market: End-user Estimate & Trend Analysis
10. Regional Market Analysis
11. North America Ultrasound guided breast biopsy Market
12. Europe Global Ultrasound guided breast biopsy Market
13. Asia Pacific Global Ultrasound guided breast biopsy Market
14. Latin America Global Ultrasound guided breast biopsy Market
15. MEA Global Ultrasound guided breast biopsy Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- CryoLife, Inc
- Baxter International, Inc
- Cohera Medical, Inc
- C.R. Bard, Inc
- Ethicon, Inc. [J&J]
- Cardinal Health
- Integra LifeSciences Holdings Corporation
- Mallinckrodt
- B. Braun Melsungen AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 725 million |
| Forecasted Market Value ( USD | $ 1725.2 million |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
